文献速递消化系统肿瘤

肝外转移模式对阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的临床影响

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
PubMed 文献 · Eur J Cancer · 2026-03-30

该多中心回顾性研究纳入647例接受阿替利珠单抗联合贝伐珠单抗一线治疗的不可切除肝细胞癌患者,评估肝外转移模式与生存及影像学进展的关系。结果显示,存在肝外转移与较短的无进展生存期和较低疾病控制率相关,但不影响总生存期;≥3个肝外转移部位与更差的总生存期、无进展生存期和疾病控制率独立相关。寡转移患者的总生存期和无进展生存期与无转移患者相同。

要点

  • 肝外转移存在与较短PFS和较低DCR相关,但不影响OS。
  • ≥3个肝外转移部位是OS、PFS和DCR的独立不良预后因素。
  • 寡转移患者OS和PFS与无肝外转移患者相同。

核心结论

  • 高转移负荷(≥3个肝外转移部位)对阿替利珠单抗联合贝伐珠单抗治疗的不可切除肝细胞癌患者预后产生负面影响。
  • 寡转移患者的总生存期和无进展生存期与无肝外转移患者相同。

研究设计与样本

  • 多中心回顾性研究,纳入6个中心接受阿替利珠单抗联合贝伐珠单抗一线治疗的不可切除肝细胞癌患者647例。
  • 中位年龄67岁,男性占86%,肝硬化占74%。

主要发现

  • 197例(30%)存在肝外转移,最常见部位为淋巴结(49%)、肺(39%)、腹膜(19%)和骨(19%)。
  • 71%的肝外转移患者仅有1个转移部位,29%有≥2个部位,8.1%有≥3个部位。
  • 肝外转移与较短PFS相关(aHR 1.23,95%CI 1.01-1.49,p=0.036),与较低DCR相关(aOR 0.62,95%CI 0.44-0.89,p=0.009),与OS无显著关联。
  • ≥3个肝外转移部位与更差OS(aHR 2.44,95%CI 1.39-4.29,p=0.02)、PFS(aHR 2.22,95%CI 1.31-3.75,p<0.01)和DCR(aOR 0.28,95%CI 0.08-0.85,p=0.035)相关。
  • 多发转移患者OS较短(P=0.026)且PFS较短(P<0.001),而寡转移患者与无转移患者OS和PFS相同。

关键数值与推荐

  • 肝外转移定义:存在任何肝外转移;转移部位数目(无、1、2、≥3);转移负荷(转移灶总数);寡转移状态(ESMO定义)。

临床怎么用

  • 对于接受阿替利珠单抗联合贝伐珠单抗治疗的不可切除肝细胞癌患者,应评估肝外转移的部位数目和负荷以辅助预后分层。
  • ≥3个肝外转移部位提示预后较差,可能需要更密切的监测或考虑强化治疗策略。
  • 寡转移患者可能获得与无肝外转移患者相似的生存获益。

局限性

  • 回顾性研究设计。
  • 未报告寡转移的具体定义标准(仅提及ESMO定义)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aim to analyze the impact on oncological outcomes of extrahepatic metastases (EM) in patients with unresectable hepatocellular carcinoma (HCC) treated by atezolizumab/bevacizumab (Atezo/Bev). METHODS: We retrospectively included patients with HCC treated with Atezo/Bev as first-line systemic treatment in 6 centers. EM patterns were assessed using the following definitions: 1) presence of EM, 2) number of EM sites (none, 1, 2, ≥3), 3) EM burden (total number of metastases) and 4) oligometastasis status (ESMO definition). We used cox and logistic regression to evaluate the associations between variables and overall survival (OS), progression free survival (PFS) and radiological progression (RECIST v1.1). RESULTS: 647 patients were enrolled with a median age of 67 years, 86% male and 74% of cirrhosis. Among the 197 patients with EM (30%), the most common metastatic sites were lymph nodes (49%), lung (39%), peritoneal (19%), and bone (19%) and 71% had a unique EM, 29% had ≥ 2 EM sites and 8.1% ≥ 3 EM sites. EM was not associated with OS but was associated with shorter PFS (adjusted hazard ratio [aHR]:1.23, 95%CI:1.01-1.49, p = 0.036) and lower disease control rate (DCR) (adjusted odds ratio [aOR]:0.62, 95%CI:0.44-0.89, p = 0.009). Three or more EM sites were associated with poorer OS (aHR: 2.44, 95%CI: 1.39-4.29, p = 0.02), PFS (aHR:2.22, 95%CI: 1.31-3.75, p < 0.01), and DCR (aOR: 0.28, 95%CI: 0.08-0.85, p = 0.035). Patients with oligometastasis have the same OS and PFS than patients without metastasis whereas patients with multiple metastasis have a shorter OS (P = 0.026) and PFS (P < 0.001). CONCLUSION: Presence of high metastatic burden negatively affects the prognosis of patients with HCC under Atezo/Bev whereas patients with oligometastasis have the same oncological outcomes than patients without EM.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vo-Quang E, Campani C, Allaire M, et al. Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Eur J Cancer. 2026. PMID: 41935493. doi:10.1016/j.ejca.2026.116704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。